Clinical trial
Study to Assess the Efficacy and Safety of Rifaximin Administered BID in the…
NCT00269412 · Bausch Health Americas, Inc., Industry · Completed
Key facts
| NCT number | NCT00269412 |
|---|---|
| Title | Study to Assess the Efficacy and Safety of Rifaximin Administered BID in the Treatment of Patients With Diarrhea-Associated Irritable Bowel Syndrome |
| Official title | Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess The Efficacy and Safety of Three Different Doses (275, 550 AND 1100 MG) of Rifaximin Administered BID For Either Two or Four Weeks in The Treatment of Patients With Diarrhea-Associated Irritable Bowel Syndrome |
| Lead sponsor | Bausch Health Americas, Inc., Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Irritable Bowel Syndrome |
| Intervention type | Drug |
| Interventions | Rifaximin |
| Enrollment | 525 |
| Start date | Dec 1, 2005 |
| Primary completion | Aug 1, 2007 |
| Completion | Sep 1, 2008 |
| First posted | Dec 23, 2005 |
| Last update posted | Nov 25, 2019 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: